Published in Genetics and Environmental Health Week, January 5th, 2005
The presentation also reviewed the safety profile of ARIMIDEX compared to tamoxifen after 68 months of follow-up. ARIMIDEX and tamoxifen remain the only drugs approved by the FDA for the primary (treatment following surgery, with or without radiation) adjuvant treatment of hormone receptor-positive postmenopausal women with early breast cancer.
"It is crucial for women to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.